The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 03, 2022

Filed:

Feb. 03, 2017
Applicant:

Mediapharma S.r.l., Chieti, IT;

Inventors:

Stefano Iacobelli, Rome, IT;

Annalisa Di Risio, Chieti, IT;

Enza Piccolo, Lanciano, IT;

Gianluca Sala, Pescara, IT;

Emily Capone, Cavallino, IT;

Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61P 35/00 (2006.01); C07K 16/18 (2006.01); A61K 47/68 (2017.01); C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 49/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 47/6803 (2017.08); A61K 39/3955 (2013.01); A61K 47/6817 (2017.08); A61K 49/0002 (2013.01); A61P 35/00 (2018.01); C07K 16/18 (2013.01); C07K 16/2851 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01);
Abstract

The present disclosure relates to the generation of an antibody that specifically recognizes and binds Endosialin, a cell surface antigen characteristic of tumor pericytes and cells of tumor stroma. The antibody has the ability to become internalized in Endosialin expressing cells and to block the activation of MAPK in PDGF stimulated human pericytes. The antibody is able to block angiogenesis induced by LGALS3BP, a known Endosialin interactor and to inhibit tumor growth alone and in combination with 1959, a humanized antibody against LGALS3BP in human osteosarcoma xenograft. Furthermore, upon conjugation of the humanized version of the anti-Endosialin antibody with a duocarmycin derivative, the resulting ADC displays potent and antigen dependent in vitro tumor cell cytotoxicity and effective antitumor efficacy in vivo. The disclosure is also related to nucleotides encoding the antibodies of the disclosure and cell expressing the antibodies.


Find Patent Forward Citations

Loading…